Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

EyePoint Pharmaceuticals Company

EYPT
US30233G2093
A2QJRU

Price

11.04
Today +/-
-1.00
Today %
-9.34 %
P

EyePoint Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the EyePoint Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the EyePoint Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the EyePoint Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze EyePoint Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

EyePoint Pharmaceuticals Stock Price History

DateEyePoint Pharmaceuticals Price
10/29/202411.04 undefined
10/28/202412.12 undefined
10/25/20249.50 undefined
10/24/20249.56 undefined
10/23/20249.96 undefined
10/22/202410.75 undefined
10/21/202410.70 undefined
10/18/202411.05 undefined
10/17/202411.15 undefined
10/16/202411.28 undefined
10/15/20249.88 undefined
10/14/202410.17 undefined
10/11/20248.83 undefined
10/10/20248.24 undefined
10/9/20248.39 undefined
10/8/20248.48 undefined
10/7/20248.71 undefined
10/4/20248.63 undefined
10/3/20248.37 undefined
10/2/20248.21 undefined
10/1/20248.00 undefined
9/30/20247.99 undefined

EyePoint Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into EyePoint Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by EyePoint Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects EyePoint Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of EyePoint Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into EyePoint Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing EyePoint Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on EyePoint Pharmaceuticals’s growth potential.

EyePoint Pharmaceuticals Revenue, EBIT and net profit per share

DateEyePoint Pharmaceuticals RevenueEyePoint Pharmaceuticals EBITEyePoint Pharmaceuticals Net Income
2029e623.4 M undefined0 undefined199.25 M undefined
2028e319.16 M undefined32.65 M undefined31.94 M undefined
2027e70.78 M undefined-160.96 M undefined-135.17 M undefined
2026e3.81 M undefined-221.48 M undefined-189.02 M undefined
2025e14.19 M undefined-182.79 M undefined-172.94 M undefined
2024e41.48 M undefined-137.23 M undefined-128.78 M undefined
202346.02 M undefined-75.07 M undefined-70.8 M undefined
202241.4 M undefined-78.94 M undefined-102.25 M undefined
202136.94 M undefined-55.28 M undefined-58.42 M undefined
202034.44 M undefined-36.7 M undefined-45.39 M undefined
201920.37 M undefined-47.86 M undefined-56.79 M undefined
20182.96 M undefined-26.27 M undefined-53.17 M undefined
20177.54 M undefined-18.11 M undefined-18.49 M undefined
20161.62 M undefined-21.77 M undefined-21.55 M undefined
201526.57 M undefined6.42 M undefined6.35 M undefined
20143.47 M undefined-13.57 M undefined-13.36 M undefined
20132.14 M undefined-12.03 M undefined-11.9 M undefined
20123.53 M undefined-10.38 M undefined-24.84 M undefined
20114.97 M undefined-10 M undefined-8.63 M undefined
201023.05 M undefined9.09 M undefined8.75 M undefined
200912.16 M undefined-4.64 M undefined-2.51 M undefined
20083.48 M undefined-24.9 M undefined-75.67 M undefined
20072.07 M undefined-102.61 M undefined-77.69 M undefined
20061.47 M undefined-27.85 M undefined-47.43 M undefined
2005620,000 undefined-14.41 M undefined-12.45 M undefined
2004270,000 undefined-6.38 M undefined-3.57 M undefined

EyePoint Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000123122343232617220343641464114370319623
------100.0050.00300.0091.67-82.61-25.00-33.3350.00766.67-96.15600.00-71.43900.0070.005.8813.8912.20-10.87-65.85-78.572,233.33355.7195.30
------------------85.0082.3577.7880.4989.13------
0000000000000000001728283341000000
-2-2-3-6-14-27-102-24-49-10-10-12-136-21-18-26-47-36-55-78-75-137-182-221-160320
------2,700.00-5,100.00-800.00-33.3339.13-250.00-333.33-600.00-433.3323.08-2,100.00-257.14-1,300.00-235.00-105.88-152.78-190.24-163.04-334.15-1,300.00-7,366.67-228.5710.03-
-1-1-1-3-12-47-77-75-28-8-24-11-136-21-18-53-56-45-58-102-70-128-172-189-13531199
---200.00300.00291.6763.83-2.60-97.33-500.00-200.00200.00-54.1718.18-146.15-450.00-14.29194.445.66-19.6428.8975.86-31.3782.8634.389.88-28.57-122.96541.94
0.220.220.250.320.520.761.121.821.831.891.952.082.32.743.063.163.534.6210.4312.8428.7637.3238.9000000
-----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The EyePoint Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the EyePoint Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                           
0.821.99.811.52.715.66.917.624.114.610.318.328.52916.938.845.322.244.9211.6144.6331.05
0.10.20.50.72.510.81.10.810.60.50.60.50.30.40.611.49.518.415.50.81
000005000000000000000000
00000000000000000.32.15.33.62.93.91
000.20.50.50.60.40.40.40.41.60.50.70.50.60.81.463.44.29.99.04
0.922.110.512.75.717.78.119.125.31612.519.329.83017.84047.641.763.1237.8172.9344.8
0.30.52.52.30.50.50.100.10.30.20.30.30.30.30.30.33.43.22.77.410.23
0000000000000000000000
000008000000000000000000
3.65.539.2120.339.436.828.823.921.64.23.42.81.91.10.431.430.127.725.222.700
0017.839.540.500000000000000000
000000100100100100200300300300300200200200200200200150
3.9659.5162.180.438.1292421.84.63.83.42.51.7131.930.631.328.625.67.610.38
4.828.170174.886.155.837.143.147.120.616.322.732.331.718.871.978.27391.7263.4180.5355.18
                                           
10.534.982.3171207.100000000000.10.10.10000.05
000000.250.250.250.260.260.270.290.290.310.320.370.450.470.530.750.771.01
-6.4-9.2-21.9-42.3-152.1-224.5-227-218.3-226.9-251.8-263.7-277-270.7-292.2-310.8-364-408.5-465.3-510.7-569.1-671.4-742.15
000.51.110.972.10.51.40.90.910.90.90.80.80.80.80.80.80.80.86
0000000000000000000000
4.125.760.9129.865.930.123.63337.413.57.614.923.320.913.311.737.68.318.5184.396.3266.32
0.41.31.53.65.62.60.30.40.30.40.70.50.71.412.92.64.24.87.45.930.53
0.2001.91.82.21.61.21.30.61.91.52.63.64.218.718.87.3915.116.918.08
000410.712.46.91.43.42.20.70.100.10.10000.91.11.238.68
0000000000000000000010.50
0008.3000000000000000.10.100
0.61.31.517.818.117.28.8353.23.32.13.35.15.321.621.411.514.823.734.587.29
0002.90000000000017.317.647.23836.629.30
007.724.22.10.30.20.200000000000000
000008.14.66.84.63.85.25.65.75.60.1211.55.920.218.720.125.6
007.727.12.18.44.874.63.85.25.65.75.60.138.319.153.158.255.349.425.6
0.61.39.244.920.225.613.6109.678.57.7910.75.459.940.564.6737983.9112.89
4.72770.1174.786.155.737.2434720.516.122.632.331.618.771.678.172.991.5263.3180.2379.21
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of EyePoint Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand EyePoint Pharmaceuticals's financial health and stability.

Assets

EyePoint Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that EyePoint Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of EyePoint Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into EyePoint Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200120022003200420052006200720082009201020112012201320142015201620172018201820192020202120222023
0000000-75-28-8-24-11-136-21-18-53-44-56-45-58-102-70
000058843332100001122220
000000000000000000000000
-1-1-3-5-14-24-2713-10-41-20012000-1220-1-358
000000054233172244031211413145225
000000000000000000145421
000000000000000000000000
-1-1-2-5-9-16-19-5-89-3-9-8-1010-16-20-21-22-56-14-50-651
0000-2-10000000000000000-2-3
0000-6-4100-2-9060-6-413-16000-33-17-3
0000-3-2100-2-9160-6-413-16000-32-150
000000000000000000000000
0000014-13000000000020030-1102-40
11025282520001004190168422923502170229
22026221918001004190168602933372160187
1,0001,000000-2,000-2,000-2,000000000000-1,0000-19,00000-3,000-1,000
000000000000000000000000
00-221-131-912-88-2-8283-31216-2322133-82185
-2.26-2.26-2.68-5.93-11.81-17.4-19.72-5.41-8.649.88-3.3-9.41-8.82-10.9210.14-16.43-20.64-22.02-22.72-56.91-14.8-50.26-67.16-1.61
000000000000000000000000

EyePoint Pharmaceuticals stock margins

The EyePoint Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of EyePoint Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for EyePoint Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the EyePoint Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the EyePoint Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the EyePoint Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the EyePoint Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the EyePoint Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the EyePoint Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the EyePoint Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

EyePoint Pharmaceuticals Margin History

EyePoint Pharmaceuticals Gross marginEyePoint Pharmaceuticals Profit marginEyePoint Pharmaceuticals EBIT marginEyePoint Pharmaceuticals Profit margin
2029e89.93 %0 %31.96 %
2028e89.93 %10.23 %10.01 %
2027e89.93 %-227.42 %-190.97 %
2026e89.93 %-5,813.14 %-4,961.14 %
2025e89.93 %-1,288.17 %-1,218.76 %
2024e89.93 %-330.84 %-310.46 %
202389.93 %-163.13 %-153.84 %
202279.9 %-190.68 %-246.98 %
202177.86 %-149.65 %-158.15 %
202083.07 %-106.56 %-131.79 %
201986.79 %-234.95 %-278.79 %
201889.93 %-887.5 %-1,796.28 %
201789.93 %-240.19 %-245.23 %
201689.93 %-1,343.83 %-1,330.25 %
201589.93 %24.16 %23.9 %
201489.93 %-391.07 %-385.01 %
201389.93 %-562.15 %-556.07 %
201289.93 %-294.05 %-703.68 %
201189.93 %-201.21 %-173.64 %
201089.93 %39.44 %37.96 %
200989.93 %-38.16 %-20.64 %
200889.93 %-715.52 %-2,174.43 %
200789.93 %-4,957.01 %-3,753.14 %
200689.93 %-1,894.56 %-3,226.53 %
200589.93 %-2,324.19 %-2,008.06 %
200489.93 %-2,362.96 %-1,322.22 %

EyePoint Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The EyePoint Pharmaceuticals earnings per share therefore indicates how much revenue EyePoint Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue EyePoint Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates EyePoint Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of EyePoint Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating EyePoint Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

EyePoint Pharmaceuticals Revenue, EBIT and net profit per share

DateEyePoint Pharmaceuticals Sales per ShareEyePoint Pharmaceuticals EBIT per shareEyePoint Pharmaceuticals Earnings per Share
2029e11.65 undefined0 undefined3.72 undefined
2028e5.96 undefined0 undefined0.6 undefined
2027e1.32 undefined0 undefined-2.53 undefined
2026e0.07 undefined0 undefined-3.53 undefined
2025e0.27 undefined0 undefined-3.23 undefined
2024e0.78 undefined0 undefined-2.41 undefined
20231.18 undefined-1.93 undefined-1.82 undefined
20221.11 undefined-2.12 undefined-2.74 undefined
20211.28 undefined-1.92 undefined-2.03 undefined
20202.68 undefined-2.86 undefined-3.54 undefined
20191.95 undefined-4.59 undefined-5.44 undefined
20180.64 undefined-5.69 undefined-11.51 undefined
20172.14 undefined-5.13 undefined-5.24 undefined
20160.51 undefined-6.89 undefined-6.82 undefined
20158.68 undefined2.1 undefined2.08 undefined
20141.27 undefined-4.95 undefined-4.88 undefined
20130.93 undefined-5.23 undefined-5.17 undefined
20121.7 undefined-4.99 undefined-11.94 undefined
20112.55 undefined-5.13 undefined-4.43 undefined
201012.2 undefined4.81 undefined4.63 undefined
20096.64 undefined-2.54 undefined-1.37 undefined
20081.91 undefined-13.68 undefined-41.58 undefined
20071.85 undefined-91.62 undefined-69.37 undefined
20061.93 undefined-36.64 undefined-62.41 undefined
20051.19 undefined-27.71 undefined-23.94 undefined
20040.84 undefined-19.94 undefined-11.16 undefined

EyePoint Pharmaceuticals business model

EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and marketing of innovative products targeting medical and eye-related conditions. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals has a diverse portfolio of products focused on the treatment of eye diseases. This includes products for the treatment of retinal diseases such as diabetic retinopathy, macular degeneration, and retinal vein occlusions, as well as products for preventing postoperative infections and relieving pain after eye surgeries. The business model of EyePoint Pharmaceuticals is based on the development and marketing of drugs and technologies tailored to the needs of patients and physicians in the field of ophthalmology. The company aims to improve patients' quality of life by offering innovative, safe, and effective products of the highest quality. One of EyePoint Pharmaceuticals' key technologies is the Durasert technology, which allows for controlled release of drugs over an extended period of time. This technology is utilized in many of the company's products, such as the Iluvien implant for treating diabetic retinopathy and macular degeneration. The company operates in various sectors, including ophthalmology, pain management, and ophthalmology. Each of these sectors has its own products and technologies tailored specifically to the needs of patients and physicians in those areas. A significant factor in EyePoint Pharmaceuticals' business model is partnerships with other companies and organizations that support collaboration in the development and marketing of new products. One such partnership is the joint venture with Ocumension Therapeutics, which aims to market EyePoint Pharmaceuticals' products in the Asian market. Overall, the company has introduced a variety of innovative products to the market that have had a significant impact on ophthalmology. These include products such as the Ozurdex implant for treating macular degeneration and uveitis, as well as the Dexycu injection for preventing postoperative inflammation and pain. In recent years, the company has made progress in the development of drugs for retinal diseases such as diabetic retinopathy and retinal vein occlusions. One such development is the Yutiq implant, specifically designed to slow the progression of diabetic retinopathy. Overall, EyePoint Pharmaceuticals has a significant influence on ophthalmology and plays a crucial role in the development of innovative products and technologies to improve patients' quality of life. The company will continue to play an important role in the medical industry by focusing on the development and marketing of products targeting specific needs of patients and physicians in the field of ophthalmology. EyePoint Pharmaceuticals is one of the most popular companies on Eulerpool.com.

EyePoint Pharmaceuticals Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

EyePoint Pharmaceuticals Revenue by Segment

Segmente20222021202020192018
Product363,000 USD308,000 USD213,000 USD16.82 M USD-
License and collaboration agreement-543,000 USD11.5 M USD1.36 M USD-
Royalty Income269,000 USD-1.7 M USD2.18 M USD-
License and Collaboration Agreements191,000 USD----
YUTIQ product---12.05 M USD-
DEXYCU product---4.78 M USD-
Collaborative research and development----1.1 M USD
Royalty----1 M USD
YUTIQ product-16.96 M USD13.88 M USD--
YUTIQ28.33 M USD----
DEXYCU product-18.35 M USD6.95 M USD--
DEXYCU11.58 M USD----
Collaborative research and development---135,000 USD-
Royalty purchase agreement-872,000 USD---
RPA868,000 USD----
Technical Assistance188,000 USD499,000 USD---
Collaborative research and development-60,000 USD255,000 USD--
Collaborative Research and Development-----

EyePoint Pharmaceuticals Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

EyePoint Pharmaceuticals Revenue by Segment

DateChinaCountry USG BUNITED KINGDOMUnited States
2022823,000 USD40.48 M USD-100,000 USD-
2021851,000 USD35.99 M USD-100,000 USD-
202011.71 M USD22.62 M USD-100,000 USD-
20191.12 M USD19.14 M USD-100,000 USD-
2018---100,000 USD2.86 M USD
2017---100,000 USD7.44 M USD
2016---100,000 USD1.52 M USD
2015---100,000 USD26.47 M USD
2014--225,000 USD-3.25 M USD

EyePoint Pharmaceuticals SWOT Analysis

Strengths

EyePoint Pharmaceuticals Inc has a strong portfolio of innovative eye care products.

The company has a robust research and development pipeline with potential for future growth and expansion.

EyePoint Pharmaceuticals Inc has a highly experienced and talented team of scientists and researchers.

The company has established strong relationships with key stakeholders, including healthcare professionals and regulatory authorities.

Weaknesses

EyePoint Pharmaceuticals Inc faces intense competition from other players in the eye care industry.

The company's dependence on a few key products for revenue generation increases its vulnerability to market fluctuations.

EyePoint Pharmaceuticals Inc may face challenges in effectively marketing and promoting its products to target customers.

The company's financial performance has been inconsistent in recent years.

Opportunities

Growing elderly population and increasing prevalence of eye-related diseases present a significant market opportunity for EyePoint Pharmaceuticals Inc.

The company can explore partnerships and collaborations to expand its global reach and enter new markets.

Advancements in technology and drug delivery systems offer opportunities for the development of innovative eye care solutions.

EyePoint Pharmaceuticals Inc can leverage its strong R&D capabilities to develop differentiated products and gain a competitive advantage.

Threats

Stringent regulatory requirements and approval processes pose a threat to the timely launch of new products.

Rapidly changing market dynamics and evolving customer preferences can impact the demand for EyePoint Pharmaceuticals Inc's products.

The company may face legal and intellectual property challenges from competitors.

Fluctuating raw material prices can influence the company's production costs and profit margins.

EyePoint Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

EyePoint Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

EyePoint Pharmaceuticals shares outstanding

The number of shares was EyePoint Pharmaceuticals in 2023 — This indicates how many shares 38.904 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue EyePoint Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates EyePoint Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of EyePoint Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating EyePoint Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

EyePoint Pharmaceuticals stock splits

In EyePoint Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.54 -0.58  (-8.31 %)2024 Q2
3/31/2024-0.42 -0.55  (-29.63 %)2024 Q1
12/31/2023-0.5 -0.33  (33.44 %)2023 Q4
9/30/2023-0.52 -0.33  (36.91 %)2023 Q3
6/30/20230.61 -0.61  (-199.89 %)2023 Q2
3/31/2023-0.7 -0.56  (19.66 %)2023 Q1
12/31/2022-0.62 -1.16  (-86.44 %)2022 Q4
9/30/2022-0.71 -0.49  (30.98 %)2022 Q3
6/30/2022-0.53 -0.52  (2.59 %)2022 Q2
3/31/2022-0.59 -0.56  (5.02 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the EyePoint Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

75/ 100

🌱 Environment

79

👫 Social

95

🏛️ Governance

50

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

EyePoint Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
12.87974 % Cormorant Asset Management, LP6,893,235855,0001/11/2024
8.59142 % Franklin Advisers, Inc.4,598,127487,70812/31/2023
8.34533 % Adage Capital Management, L.P.4,466,4202,729,91712/31/2023
7.58006 % Suvretta Capital Management, LLC4,056,847564,70012/31/2023
4.61232 % T. Rowe Price Associates, Inc.2,468,5131,099,85512/31/2023
4.36806 % EW Healthcare Partners2,337,786-1,153,13512/31/2023
3.80056 % The Vanguard Group, Inc.2,034,060593,33612/31/2023
3.67848 % BlackRock Institutional Trust Company, N.A.1,968,721371,95412/31/2023
2.91232 % T. Rowe Price Investment Management, Inc.1,558,6751,558,67512/31/2023
2.72490 % Columbia Threadneedle Investments (US)1,458,3671,448,01812/31/2023
1
2
3
4
5
...
10

EyePoint Pharmaceuticals Executives and Management Board

Ms. Nancy Lurker65
EyePoint Pharmaceuticals Executive Vice Chairman of the Board (since 2016)
Compensation 3.45 M
Dr. Jay Duker64
EyePoint Pharmaceuticals President, Chief Executive Officer (since 2016)
Compensation 2.06 M
Mr. Michael Pine47
EyePoint Pharmaceuticals Chief Corporate Development and Strategy Officer
Compensation 1.61 M
Mr. Scott Jones56
EyePoint Pharmaceuticals Senior Vice President, Chief Commercial Officer
Compensation 1.46 M
Mr. George Elston58
EyePoint Pharmaceuticals Chief Financial Officer, Executive Vice President
Compensation 1.45 M
1
2
3
4

EyePoint Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Oncosil Medical Stock
Oncosil Medical
SupplierCustomer0,26-0,30-0,040,13-0,40-0,69
Betta Pharmaceuticals A Stock
Betta Pharmaceuticals A
SupplierCustomer-0,19-0,42-0,390,49-0,25-0,47
Alimera Sciences Stock
Alimera Sciences
SupplierCustomer-0,34-0,070,29--0,450,12
Ocumension Stock
Ocumension
SupplierCustomer-0,35-0,530,420,65-0,35-
Harrow Health Stock
Harrow Health
SupplierCustomer-0,530,32-0,310,38-0,040,52
AmerisourceBergen Stock
AmerisourceBergen
SupplierCustomer-0,66-0,020,66-0,420,210,61
McKesson Stock
McKesson
SupplierCustomer-0,80-0,540,68-0,380,310,58
1

Most common questions regarding EyePoint Pharmaceuticals

What values and corporate philosophy does EyePoint Pharmaceuticals represent?

EyePoint Pharmaceuticals Inc represents a strong commitment to improving patient outcomes through advanced ophthalmic therapeutic solutions. With a focus on innovation, the company is dedicated to developing and commercializing sustained-release drug delivery technologies. EyePoint Pharmaceuticals strives to address unmet medical needs and provide convenient treatment options to patients suffering from serious eye conditions. By leveraging its expertise and cutting-edge research, EyePoint Pharmaceuticals aims to enhance the quality of life for individuals worldwide.

In which countries and regions is EyePoint Pharmaceuticals primarily present?

EyePoint Pharmaceuticals Inc is primarily present in several countries and regions. These include the United States, where the company is headquartered, as well as Europe, specifically Germany, France, and the United Kingdom. Additionally, EyePoint Pharmaceuticals Inc has a presence in selected markets in Asia, including Japan. With its global reach, EyePoint Pharmaceuticals Inc aims to bring innovative ophthalmic products and therapies to patients worldwide.

What significant milestones has the company EyePoint Pharmaceuticals achieved?

EyePoint Pharmaceuticals Inc has achieved several significant milestones in its history. The company has successfully developed and commercialized innovative ophthalmic treatments, making a positive impact on patient care. EyePoint Pharmaceuticals Inc received FDA approval for its sustained-release intraocular implant, DEXYCU®, which is used for treating inflammation after cataract surgery. Additionally, the company gained FDA approval for YUTIQ®, a micro-insert used for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. These milestones demonstrate EyePoint Pharmaceuticals Inc's commitment to advancing therapeutic options in the field of ophthalmology.

What is the history and background of the company EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals Inc is a renowned pharmaceutical company specializing in developing and commercializing innovative ophthalmic products. Founded in 1987, EyePoint has a rich history of advancing patient care in the field of ophthalmology. With a strong focus on sustained-release drug delivery systems, the company has successfully developed and received regulatory approvals for several cutting-edge ophthalmic treatments. EyePoint Pharmaceuticals Inc continues to thrive as a leading player in the industry, catering to the needs of patients worldwide. With its commitment to innovation and improving eye health, EyePoint Pharmaceuticals Inc has become a trusted name in the pharmaceutical sector.

Who are the main competitors of EyePoint Pharmaceuticals in the market?

The main competitors of EyePoint Pharmaceuticals Inc in the market are Aerie Pharmaceuticals Inc and Ocular Therapeutix Inc.

In which industries is EyePoint Pharmaceuticals primarily active?

EyePoint Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals Inc is a biopharmaceutical company specializing in the development and commercialization of innovative ophthalmic products. The business model of EyePoint Pharmaceuticals Inc revolves around developing sustained-release drug delivery systems for the treatment of serious eye diseases. By utilizing its proprietary technologies, the company aims to improve patients' outcomes by providing long-lasting and targeted drug delivery options. EyePoint Pharmaceuticals Inc focuses on developing and commercializing products addressing unmet medical needs, ultimately enhancing the quality of life for individuals suffering from various eye conditions.

What is the P/E ratio of EyePoint Pharmaceuticals 2024?

The EyePoint Pharmaceuticals P/E ratio is -3.33.

What is the P/S ratio of EyePoint Pharmaceuticals 2024?

The EyePoint Pharmaceuticals P/S ratio is 10.35.

What is the Quality Investing of EyePoint Pharmaceuticals?

The Quality Investing for EyePoint Pharmaceuticals is 5/10.

What is the revenue of EyePoint Pharmaceuticals 2024?

The expected EyePoint Pharmaceuticals revenue is 41.48 M USD.

How high is the profit of EyePoint Pharmaceuticals 2024?

The expected EyePoint Pharmaceuticals profit is -128.78 M USD.

What is the business model of EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that develops and markets innovative drugs for body tissues and eye diseases. The company's business model focuses on the development, manufacturing, and marketing of therapeutics for chronic eye diseases such as macular degeneration, diabetic retinopathy, and uveitis. EyePoint Pharmaceuticals specializes in strategic partnerships and collaborations with renowned pharmaceutical companies and global organizations. The company offers drug solutions such as Iluvien, used for the treatment of macular degeneration, and Yutiq, intended for chronic uveitis therapy. Iluvien is a steroid implant composed of a unique formulation of fluocinolone acetonide (FAc) and a biopolymer that slowly degrades during use. It has a unique ability to exert a sustained effect on eye disease, significantly reducing the need for repeated intravitreal injections. Iluvien is approved in Europe and Canada and has been submitted to the US Food and Drug Administration (FDA). Yutiq is a steroid implant developed for the treatment of chronic uveitis. It is implanted into the posterior chamber of the eye and releases the active ingredient triamcinolone acetonide (TAc) to reduce inflammation. Yutiq has been approved by the FDA and is currently available in the United States. In addition, EyePoint Pharmaceuticals also offers Dexpel, a technology platform for long-lasting surgical implants. This platform can be utilized in various medical fields such as oncology, orthopedics, and neurosurgery to control drug release, prolong treatment duration, and reduce the need for repeated injections. EyePoint Pharmaceuticals also pursues a diversification strategy to expand its product portfolio and create stable growth. This includes collaborating with other companies to provide technology solutions and services tailored to the needs of customers. Overall, the business model of EyePoint Pharmaceuticals aims to bring innovative drugs to the market that enable effective treatment of eye diseases and significantly improve patients' quality of life. The company relies on a combination of well-established and innovative technologies to control drug release and ensure optimal therapy.

What is the EyePoint Pharmaceuticals dividend?

EyePoint Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does EyePoint Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for EyePoint Pharmaceuticals or the company does not pay out a dividend.

What is the EyePoint Pharmaceuticals ISIN?

The ISIN of EyePoint Pharmaceuticals is US30233G2093.

What is the EyePoint Pharmaceuticals WKN?

The WKN of EyePoint Pharmaceuticals is A2QJRU.

What is the EyePoint Pharmaceuticals ticker?

The ticker of EyePoint Pharmaceuticals is EYPT.

How much dividend does EyePoint Pharmaceuticals pay?

Over the past 12 months, EyePoint Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyePoint Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of EyePoint Pharmaceuticals?

The current dividend yield of EyePoint Pharmaceuticals is .

When does EyePoint Pharmaceuticals pay dividends?

EyePoint Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of EyePoint Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is EyePoint Pharmaceuticals located?

EyePoint Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EyePoint Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EyePoint Pharmaceuticals from 10/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/29/2024.

When did EyePoint Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/29/2024.

What was the dividend of EyePoint Pharmaceuticals in the year 2023?

In the year 2023, EyePoint Pharmaceuticals distributed 0 USD as dividends.

In which currency does EyePoint Pharmaceuticals pay out the dividend?

The dividends of EyePoint Pharmaceuticals are distributed in USD.

All fundamentals about EyePoint Pharmaceuticals

Our stock analysis for EyePoint Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyePoint Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.